Urodynamic Assessment of Poor Responders After Botulinum Toxin-A Treatment for Overactive Bladder

Urology

Volumn 71, Issue 3, 2008, Pages 455-459

  Sahai, Arun ^a   Khan, Mohammad Shamim ^a   Le Gall, Nicolas ^b   Dasgupta, Prokar ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; OXYBUTYNIN; PLACEBO; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOMETRY; FEMALE; HEALTH CARE QUALITY; HUMAN; IMPAIRED BLADDER EMPTYING; MALE; MEDICAL ASSESSMENT; OVERACTIVE BLADDER; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; URINARY TRACT INFECTION; URODYNAMICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 40649112120     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.039     Document Type: Article

References (13)

1. Sahai A., Khan M., and Fowler C.J. Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn 24 (2005) 2-12
2. Schurch B., de Sèze M., Denys P., et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 (2005) 196-200
3. Sahai A., Khan M.S., and Dasgupta P. Efficacy of botulinum toxin-A in treating idiopathic detrusor overactivity: results from a single-centre, randomized, double-blind, placebo-controlled trial. J Urol 177 (2007) 2231-2236
4. Schmid D.M., Sauermann P., Werner M., et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176 (2006) 177-185
5. Schafer W., Abrams P., Liao L., et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21 (2002) 261-274
6. Harper M., Popat R.B., Dasgupta R., et al. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92 (2003) 325-326
7. Sahai A., Kalsi V., Khan M.S., et al. Techniques for the intradetrusor administration of botulinum toxin. BJU Int 97 (2006) 675-678
8. Santos J.I., Swensen P., and Glasgow L.A. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 68 (1981) 50-54
9. Schurch B, De Seze M, Denys P, et al: Reduction in neurogenic incontinence episodes following treatment with botulinum toxin A: potential predictors of response. Eur Urol Suppl 4: 164 [Abstract 646].
10. Comperat E., Reitz A., Delcourt A., et al. Histologic features in the urinary bladder wall affected from neurogenic overactivity: a comparison of inflammation, oedema and fibrosis with and without injection of Botulinum toxin type A. Eur Urol 50 (2006) 1058-1064
11. Kuo H.C. Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int 75 (2005) 170-174
12. Giannantoni A., Costantini E., Di Stasi S.M., et al. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 49 (2006) 704-709
13. Kessler T.M., Danuser H., Schumacher M., et al. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn 24 (2005) 231-236